Atorvo+™
Atorvo+ Development
Atorvo+™ is the first product emerging from Indication Bioscience’s Statin+™ platform, a next-generation approach to fixed-dose combination therapy designed to preserve established lipid-lowering efficacy while improving long-term tolerability and adherence.
Atorvo+™ combines atorvastatin, the active component of Lipitor®—the world’s most widely prescribed cholesterol-lowering therapy—with a proprietary, well-characterized small molecule in a rationally designed fixed-dose formulation. The program is intended to address the real-world limitations of standard statin therapy, where adverse effects and metabolic liabilities frequently lead to dose reduction or discontinuation.
A randomized Phase I pharmacokinetic and safety study was successfully completed in 2025, demonstrating a favorable tolerability profile and a differentiated pharmacokinetic profile relative to atorvastatin alone. These results provide the foundation for the next stage of development, with a Phase II/III program in planning under a streamlined regulatory pathway.
Atorvo+™ represents the first of multiple differentiated fixed-dose combinations being advanced under the Statin+™ platform, which is designed for scalable expansion across additional major statins, including rosuvastatin, simvastatin, and lovastatin, leveraging a consistent formulation, IP, and regulatory strategy.
Pre-Clinical
At Indication Bioscience, our pre-clinical research lays the foundation for transformative therapies. By combining rigorous scientific methods with innovative technologies, we evaluate the safety, efficacy, and unique advantages of our drug candidates before advancing to clinical trials. Our lead program, Atorvo+, has demonstrated compelling pre-clinical data, showcasing its potential to address statin intolerance while maintaining effective cholesterol management. These findings reinforce our commitment to advancing therapies that solve real-world challenges and improve patient outcomes.
Accelerated Pathway
At Indication Bioscience, we are pursuing an accelerated development strategy to bring innovative cardiovascular therapies to patients more efficiently.
By leveraging the existing safety and efficacy data of well-characterized compounds, our approach reduces the time and cost typically associated with early-stage drug development—without compromising scientific or regulatory rigor.
This streamlined model enables us to focus on addressing critical unmet needs in cardiovascular care, such as improving statin tolerability and long-term adherence, while advancing high-quality programs like Atorvo+™ toward clinical proof of concept with greater speed and precision.